For more information about each sponsor, please click on their logo.
National Cancer Society of Malaysia (NCSM)
The National Cancer Society Malaysia (NCSM), also known as Persatuan Kebangsaan Kanser Malaysia, is a registered, tax exempt charity body established in 1966 under the laws of the Malaysian Societies Act and Registrar of Societies Malaysia. NCSM is the first not-for-profit cancer organisation in Malaysia that provides education, care and support services for people affected by cancer. It was founded by Datoâ€™ Dr. S.K. Dharmalingam and officially launched by YAB Tun Abdul Razak in 1966. It is under the distinguished patronage of the Sultan of Perak. The Society is financed entirely by contributions and donations from the public.
Malaysia Convention & Exhibition Bureau
Malaysia Convention & Exhibition Bureau (MyCEB) is a non-profit organisation established in 2009 by the Ministry of Tourism and Culture Malaysia to grow the countryâ€™s business tourism industry. The inception is in line with Malaysiaâ€™s Economic Transformation Programme (ETP) to elevate the country to be developed-nation status by year 2020. MyCEB aims to further strengthen Malaysiaâ€™s global appeal and position as the leading destination for international meetings, incentives, conventions, trade exhibitions and major events. The bureau identifies potential business event leads, facilitates bidding processes, promotes government and industry collaborations, as well as provides event support and marketing services, including consultation on local products and services. As the national bureau, MyCEB acts as a catalyst for product and industry developments.
Ministry of Tourism and Culture Malaysia
VISION Developing Malaysia as a world class tourist and cultural destination by year 2020, as well as building the national identity based on arts, culture and heritage. MISSION To drive the tourism and culture sectors as the catalyst for a sustainable socioeconomic growth, as well as to strengthen, conserve and preserve national arts, culture and heritage. MINISTRY'S POLICY STATEMENT To propel competitive and sustainable tourism and culture sectors towards the socio-economic development of the country. OBJECTIVES To strengthen the arts, culture and heritage towards enhancing national unity based on the National Cultural Policy; To enhance the synergy and cooperation among the tourism and culture industry players towards making Malaysia the preferred tourist and cultural destinations; To strengthen the tourism and culture sectors towards empowering the nation's economy; To promote Malaysia's uniqueness in arts, culture and heritage as the main catalyst for the growth in tourism and culture sectors; and To develop knowledgeable, skilled, creative and innovative human capital in tourism and culture sectors.
Our Mission Marketing Malaysia as a destination of excellence and to make the tourism industry a major contributor to the socio-economic development of the nation. Our Objectives Promote Malaysia as an outstanding tourist destination. Showcase Malaysia's unique wonders, attractions and cultures. Enhance Malaysia's share market for meetings, incentives, conventions and exhibitions (MICE). Increase Malaysia's tourism revenue by increasing tourist numbers to Malaysia and extend their length of stay. Encourage tourism and its related industries in Malaysia. Help develop domestic tourism and promote new investments in the country, as well as provide increased employment opportunities. The growth of tourism would also contribute positively to the country's economic development and quality of life. Our History The Tourist Development Corporation of Malaysia (TDC) was established on 10 August 1972 as an agency under the former Ministry of Trade and Industry by an Act of Parliament. With the inception of the Ministry of Culture, Arts and Tourism on 20 May 1987, TDC was moved to this new ministry; and became the Malaysia Tourism Promotion Board (MTPB) through the Malaysia Tourism Promotion Board Act 1992. Popularly known as Tourism Malaysia, its full focus is on promoting Malaysia domestically and internationally.
MSD is one of the world's leading healthcare companies, with its headquarters in the USA (Merck & Co., Inc., Kenilworth, NJ, USA). In Switzerland, MSD is one of the most important pharmaceutical research companies. From our base at Lucerne we serve the Swiss healthcare market and support more than 70 subsidiaries across Europe, Canada, the Middle East, Africa, Brazil, India, and China.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines, as well as many of the worldâ€™s best-known consumer healthcare products. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world.
Roche concentrates exclusively on innovative medicines and diagnostic approaches that offer decisive advantages over existing products and solutions. Our aim is to continue tailoring medicine as closely as possible to patientsâ€™ needs. As one of the worldâ€™s leading healthcare companies, and given our combined strengths in pharmaceuticals and diagnostics, thereâ€™s no one better suited for the task of developing personalised medicine.
Since its inception, Tata Trusts have played a pioneering role in transforming traditional ideas of charity and introducing the concept of philanthropy to make a real difference to communities.Through grant-making, direct implementation and co-partnership strategies, the Trusts support and drive innovation in the areas of healthcare and nutrition; water and sanitation; energy; education; rural livelihoods; natural resource management; urban poverty alleviation; enhancing civil society and governance; media, arts, crafts and culture; and diversified employment.
American Cancer Society
The American Cancer Society is a global grassroots force of 2.5 million volunteers saving lives and fighting for every birthday threatened by every cancer in every community. As the largest voluntary health organization in the US, the Society's efforts have contributed to a 22 percent decline in cancer death rates in the U.S. since 1991, and a 50 percent drop in smoking rates. Thanks in part to our progress; 14.5 million Americans who have had cancer and countless more who have avoided it will celebrate more birthdays this year. We are determined to finish the fight against cancer. We are finding cures as the nation's largest private, not-for-profit investor in cancer research, ensuring people facing cancer have the help they need and continuing the fight for access to quality health care, lifesaving screenings, clean air, and more. For more information, to get help, or to join the fight, call us anytime, day or night, at +1-800-227-2345 or visit cancer.org.
Canadian Partnership Against Cancer (CPAC)
The Canadian Partnership Against Cancer was created by the federal government in 2006 with funding through Health Canada to work with Canadaâ€™s cancer community to reduce the incidence of cancer, lessen the likelihood of Canadians dying from cancer, and enhance the quality of life of those affected by cancer. As the steward of the Canadian Strategy for Cancer Control, the Partnership works with partners to reduce the burden of cancer for Canadians. Visit www.partnershipagainstcancer.ca .
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life â€“ from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.
Access Accelerated (AA) is a unique cross-industry collaboration that seeks to reduce barriers to prevention, treatment and care for NCDs in lower- and middle-income countries through health systems strengthening and alignment with Universal Health Coverage objectives and priorities. For the first time, 24 global biopharmaceutical companies have come together to bring their global reach and local expertise in partnership with countries, civil society, multilaterals and NGOs to support cross-sectoral dialogue and drive on-the-ground implementation and action plans to address NCDs.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Bayer is a Life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture. With innovative products, Bayer is contributing to finding solutions to some of the major challenges of our time.
Cancer Council Australia
Cancer Council is Australiaâ€™s leading cancer charity working across every aspect of every cancer. Every day, Cancer Council supports families affected by cancer when they need it most, works with the community to change laws and policies to reduce cancer risks and improve cancer care, empowers Australians to reduce their cancer risk, and funds more world-class cancer research than any other-non government organisation in Australia to reduce the impact of cancer. Thanks to the support of the Australian public, Cancer Council is getting closer to a cancer free future every minute, every hour, every day
Cancer Research UK (CRUK)
Cancer Research UK is the worldâ€™s largest independent funder of cancer research. Its vision is to bring forward the day when all cancers are cured. Since 1902 CRUK has found new ways to prevent, diagnose and treat cancer. CRUK-funded scientistsâ€™ pioneered early radiotherapy, developed some of the worldâ€™s top cancer drugs and discovered the tumour suppressor gene, p53. Its work has saved millions of lives across the world. CRUK invests $500m annually in world-leading research across all 200 different types of cancer, working with partners in Europe, North America and Asia to accelerate research progress. It provides information to those affected by cancer, works to increase cancer awareness, and uses its powerful, independent voice to keep cancer at the top of the political agenda. CRUK funds some of the worldâ€™s leading experts in tobacco research and is a key player in international tobacco control. It became a full UICC member in 1986.
China Anti-Cancer Association (CACA)
Established in 1984, the Chinese Anti-Cancer Association (CACA) is a non-government and non- profit organization. CACA is dedicated to increase the survival rate, decrease the incidence and mortality rates of cancer, and improve the cancer control in China. CACA plays an important role in promoting academic exchange, organizing public education, establishing collaboration with international cancer societies, and providing data and advices to the Chinese government for making strategies and policies on cancer control. The branches are consist of 45 professional societies, 47 full membership organizations, and 30 local anti-cancer associations with a total membership exceeding 47,000.
ECS-Screening is a Swiss company that has pioneered the development of two unique laboratory tests for the detection of circulating progastrin. The presence of progastrin in the blood is linked to the presence of tumor cells. CancerREAD Smart helps health care providers screen patients for many cancer types, such as breast and colorectal cancers, even in their early stages. CancerREAD Lab helps doctors monitor how their patientsâ€™ cancers respond to therapy
National Cancer Institute (NCI)
The National Cancer Institute (NCI) is the federal government's principal agency for cancer research and training. The NCI coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.
Novartis Oncology is a global leader in transforming outcomes for people with cancer. We offer a wide range of innovative therapies to help meet patient needs and have one of the strongest, most productive pipelines in the industry. Our research is driven by a distinctive scientific and clinical strategy focused on precision oncology â€“ understanding how cancer develops on a genomic level and developing drugs that hone in on those targets. For more information, visit www.novartisoncology.com.
Prevent Cancer Foundation
The mission of the Prevent Cancer FoundationÂ® is saving lives across all populations through cancer prevention and early detection. Our vision is to Stop Cancer Before It Starts!Â® When the Prevent Cancer FoundationÂ® was founded in 1985, the concept of cancer prevention and early detection was not widely embraced by the medical community or the general public. Today, it is at the forefront of reducing cancer incidence and death. The Prevent Cancer FoundationÂ® extends its mission in four key areas: â€˘ Funding research that helps increase insight into the disease to allow us to understand how to prevent cancer or detect it early when it can be more successfully treated; â€˘ Educating people about how they can prevent cancer and detect it early through healthy lifestyle choices, vaccinations and medical screenings; â€˘ Reaching out to communities through programs that allow us to fund nationally and globally and act locally. By empowering those who know their communities best, we are able to help implement life-saving programs that benefit all populations, especially the medically underserved; â€˘ Engaging legislators and regulators through education and advocacy to promote the enactment of laws and regulations that support cancer research and prevention. To learn more, visit www.preventcancer.org
Susan G. Komen
In 1980, Nancy G. Brinker promised her dying sister, Susan, that she would do everything in her power to end breast cancer forever. In 1982, that promise became the Susan G. KomenÂ® organization and the beginning of a global movement. What was started with $200 and a shoebox full of potential donor names has now grown into the worldâ€™s largest nonprofit source of funding for the fight against breast cancer. To date, weâ€™ve invested more than $2.6 billion in groundbreaking research, community health outreach, advocacy and programs in more than 60 countries. Our efforts helped reduce death rates from breast cancer by 37 percent between 1990-2013; and have helped improve the five-year relative survival rate for early stage cancers in the U.S. from about 74 to 99 percent. And we wonâ€™t stop until our promise is fulfilled.
American Society of Clinical Oncology (ASCO)
Founded in 1964, the American Society of Clinical Oncology is the world's leading professional organization for physicians and oncology professionals caring for people with cancer. Our Mission Conquering cancer through research, education, and promotion of the highest quality patient care. Our Vision A world where cancer is prevented or cured, and every survivor is healthy. ASCO Promotes and Provides For: Lifelong learning for oncology professionals, Cancer research, An improved environment for oncology practice, Access to quality cancer care, A global network of oncology expertise, and Educated and informed patients with cancer.
â€“ A. Ramsay Sime Darby Healthcare
The mission of Ramsay Sime Darby Health Care is to provide the best healthcare in Malaysia, Indonesia and throughout Asia by delivering award-winning private healthcare, delivered by an exceptional team of specialists and healthcare professionals at the forefront of clinical care in the region.